Evidence map›Paper›PMID 38146372›Full record

ArticleFrontiers in immunology2023

Polyinosinic: polycytidylic acid induced inflammation enhances while lipopolysaccharide diminishes alloimmunity to platelet transfusion in mice.

Johnson Q Tran, Marcus O Muench, Betty Gaillard, Orsolya Darst, Mary M Tomayko, Rachael P Jackman

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Mouse Models of Platelet Alloimmunization and Refractoriness.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  3. Immune response to platelet transfusions.Current opinion in hematology · 2025
    Review
  4. Development andNanoscale advances · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Johnson Q TranVitalant Research Institute, San Francisco, CA, United States.
Marcus O MuenchVitalant Research Institute, San Francisco, CA, United States.
Betty GaillardVitalant Research Institute, San Francisco, CA, United States.
Orsolya DarstVitalant Research Institute, San Francisco, CA, United States.
Mary M TomaykoDepartment of Dermatology, Yale University School of Medicine, New Haven, CT, United States.
Rachael P JackmanVitalant Research Institute, San Francisco, CA, United States.
Vitalant · USUniversity of California, San Francisco · USYale University · US

Funding

The impact of illness and medical treatments on the alloantibody response to platelet transfusionR01HL144501 · NHLBI · VITALANT · PI JACKMAN, RACHAEL PERETZ · 2019 to 2022
$3.0M
NHLBI NIH HHS R01 HL144501
6 · The paper itself

Abstract

Introduction: Alloimmune responses against platelet antigens, which dominantly target the major histocompatibility complex (MHC), can cause adverse reactions to subsequent platelet transfusions, platelet refractoriness, or rejection of future transplants. Platelet transfusion recipients include individuals experiencing severe bacterial or viral infections, and how their underlying health modulates platelet alloimmunity is not well understood. Methods: This study investigated the effect of underlying inflammation on platelet alloimmunization by modelling viral-like inflammation with polyinosinic-polycytidylic acid (poly(I:C)) or gram-negative bacterial infection with lipopolysaccharide (LPS), hypothesizing that underlying inflammation enhances alloimmunization. Mice were pretreated with poly(I:C), LPS, or nothing, then transfused with non-leukoreduced or leukoreduced platelets. Alloantibodies and allogeneic MHC-specific B cell (allo-B cell) responses were evaluated two weeks later. Rare populations of allo-B cells were identified using MHC tetramers. Results: Relative to platelet transfusion alone, prior exposure to poly(I:C) increased the alloantibody response to allogeneic platelet transfusion whereas prior exposure to LPS diminished responses. Prior exposure to poly(I:C) had equivalent, if not moderately diminished, allo-B cell responses relative to platelet transfusion alone and exhibited more robust allo-B cell memory development. Conversely, prior exposure to LPS resulted in diminished allo-B cell frequency, activation, antigen experience, and germinal center formation and altered memory B cell responses. Discussion: In conclusion, not all inflammatory environments enhance bystander responses and prior inflammation mediated by LPS on gram-negative bacteria may in fact curtail platelet alloimmunization.

Indexed as

LipopolysaccharidesPlatelet TransfusionAnimalsHistocompatibility AntigensInflammationMiceMice, Inbred BALB CPoly CPoly I-CHistocompatibility AntigensLipopolysaccharidesPoly CPoly I-Calloantibodiesalloimmunizationinflammationlipopolysaccharideplateletspoly(I:C)underlying health

Identifiers

PMID38146372
PMCPMC10749330
OpenAlexW4389566820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.